Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
14.48
-0.32 (-2.16%)
At close: Feb 5, 2026, 4:00 PM EST
14.12
-0.36 (-2.49%)
After-hours: Feb 5, 2026, 7:46 PM EST
Contineum Therapeutics Employees
Contineum Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 10 or 32.26% compared to the previous year.
Employees
41
Change (1Y)
10
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,448,463
Market Cap
528.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| REGENXBIO | 353 |
| Lyell Immunopharma | 300 |
| Vor Biopharma | 154 |
| Lexicon Pharmaceuticals | 103 |
| Invivyd | 100 |
| Keros Therapeutics | 82 |
| Lexeo Therapeutics | 61 |
CTNM News
- 8 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 2 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 2 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
- 2 months ago - Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
- 2 months ago - Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
- 3 months ago - Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 5 months ago - Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire